Proton Bio is a subsidiary of Proton Co., Ltd., mainly engaged in gene and cell therapy CDMO service provider, focusing on the field of gene and cell therapy CDMO, providing end-to-end gene and cell therapy process development and production integration services, accelerating the development of drugs from research to commercialization transformation of production. The company recently received 520 million yuan in Series B financing. Investors include Hillhouse, Advanced Manufacturing Industry Investment Fund Phase II, Huimei Capital, Yuemin Investment, Shanghai Chuangfeng Medico Private Equity Fund, Huashan Ruilian Fund (Huatai Zijin), Fosun Pharma, China Merchants Capital, China Merchants Securities, etc.
This article is reproduced from: https://www.itjuzi.com/investevent/13496046
This site is for inclusion only, and the copyright belongs to the original author.